ADRX-0405 dose-escalation completion
ADRX-0405 is a STEAP1-directed ADC in Phase 1a/b trial NCT06710379. The company’s June 2026 update targets Phase 1a completion in Q4 2026.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- US and China IND clearances are already observed; the candidate concerns a later study milestone.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Company target: Q4 2026; exact day/current outcome unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links adcentrx.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof.
Potential outcome market
Will Adcentrx publicly confirm completion of ADRX-0405 Phase 1a dose escalation by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.